Cytokinetics Inc (CYTK) average volume reaches $1.73M: Is Wall Street expecting a rally?

On Friday, Cytokinetics Inc (NASDAQ: CYTK) opened lower -7.80% from the last session, before settling in for the closing price of $40.52. Price fluctuations for CYTK have ranged from $37.46 to $75.71 over the past 52 weeks.

During the last 5-year period, the sales growth of Healthcare Sector giant was 44.31%. Company’s average yearly earnings per share was noted -8.38% at the time writing. With a float of $115.33 million, this company’s outstanding shares have now reached $118.21 million.

Let’s determine the extent of company efficiency that accounts for 498 employees. In terms of profitability, gross margin is -890.46%, operating margin of -2902.72%, and the pretax margin is -3191.11%.

Cytokinetics Inc (CYTK) Insider Activity

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cytokinetics Inc is 2.52%, while institutional ownership is 109.77%. The most recent insider transaction that took place on Apr 03 ’25, was worth 17,744. In this transaction Director of this company sold 450 shares at a rate of $39.43, taking the stock ownership to the 14,658 shares. Before that another transaction happened on Mar 31 ’25, when Company’s President & CEO sold 15,000 for $40.75, making the entire transaction worth $611,250. This insider now owns 427,629 shares in total.

Cytokinetics Inc (CYTK) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around -8.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.31% during the next five years compared to -20.02% drop over the previous five years of trading.

Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators

Check out the current performance indicators for Cytokinetics Inc (CYTK). In the past quarter, the stock posted a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 239.51.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.28, a number that is poised to hit -1.37 in the next quarter and is forecasted to reach -4.67 in one year’s time.

Technical Analysis of Cytokinetics Inc (CYTK)

Looking closely at Cytokinetics Inc (NASDAQ: CYTK), its last 5-days average volume was 2.95 million, which is a jump from its year-to-date volume of 1.73 million. As of the previous 9 days, the stock’s Stochastic %D was 19.48%. Additionally, its Average True Range was 2.82.

During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 2.09%, which indicates a significant decrease from 4.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.80% in the past 14 days, which was higher than the 52.97% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $45.02, while its 200-day Moving Average is $51.14. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $39.69. Second resistance stands at $42.02. The third major resistance level sits at $43.42. If the price goes on to break the first support level at $35.96, it is likely to go to the next support level at $34.56. Should the price break the second support level, the third support level stands at $32.23.

Cytokinetics Inc (NASDAQ: CYTK) Key Stats

There are currently 118,411K shares outstanding in the company with a market cap of 4.42 billion. Presently, the company’s annual sales total 18,470 K according to its annual income of -589,530 K. Last quarter, the company’s sales amounted to 16,930 K and its income totaled -150,020 K.